Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
Antonis C. Antoniou(Weatherford College), Katherine L. Nathanson(Translational Therapeutics (United States)), Efrat Dagan(University of Haifa), Hans Ehrencrona(Lund University), Kathleen Claes(Statistics Belgium), Eitan Friedman(University of Pennsylvania), Flavio Lejbkowicz(Carmel Medical Center), Katja Harbst(Lund University), Lenka Foretová(Masaryk Memorial Cancer Institute), Ruth Gershoni Baruch(Rambam Health Care Campus), Tair Kontorovich(Sheba Medical Center), Bella Kaufman(NYU Langone Health), Irene L. Andrulis(University of Toronto), Yuan Chun Ding(University of Copenhagen), Csilla I. Szabo(University of Delaware), Jacques Simard(Université Laval), Gord Glendon(University Health Network), Heli Nevanlinna(University of Helsinki), Susan L. Neuhausen(City of Hope), Susan M. Domchek(University City Science Center), Michal Zikán(Charles University), Lone Sunde(Aalborg University Hospital), Anne‐Marie Gerdes(Copenhagen University Hospital), Bernardo Bonanni(European Institute of Oncology), Gisela Barbany(Karolinska Institutet), Gad Rennert(Technion – Israel Institute of Technology), Bernard Peissel(Sapienza University of Rome), Xianshu Wang(Kunming University of Science and Technology), Tuomas Heikkinen(University of Helsinki), Mark H. Greene(Cancer Institute (WIA)), Per Karlsson(University of Gothenburg), Paolo Peterlongo(IFOM), Amanda B. Spurdle(QIMR Berghofer Medical Research Institute), Paolo Radice(IFOM), Hilmi Özçelik(Mount Sinai Hospital), Yael Laitman(Sheba Medical Center), Lesley McGuffog(University of Cambridge), Loris Bernard(European Institute of Oncology), Zachary Fredericksen(Karolinska University Hospital), Sue Healey(QIMR Berghofer Medical Research Institute), Johanna Rantala(Karolinska University Hospital), Mads Thomassen(Odense University Hospital), Olga M. Sinilnikova(Hospices Civils de Lyon), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Shimrit Cohen(Sheba Medical Center), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Alessandra Viel(Centro di Riferimento Oncologico), Fergus J. Couch(Mayo Clinic)
Cited by 116
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k